In this second segment of Bob Proulx’s presentation to investors at the 2016 NobleCon meeting, he answers the question of how magnetic relaxometry might be used in cancer medicine. This video introduces roles for magnetic relaxometry in early cancer detection, cancer staging, and therapeutic monitoring. It also outlines the unique capabilities of magnetic relaxometry relative to MRI, ultrasound, X-ray imaging, blood biomarkers, and biopsies.
Phase 2 HER2 Clinical Trial Manufacturing Commenced, WSU Imaging Optimisation Program Underway
Highlights Dr Nina Webster appointed as IBX Non-Executive Director, bringing significant clinical development expertise and corporate experienceto the IBX Board ahead of HER2 Breast cancer